AOBI — American Oriental Bioengineering Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for American Oriental Bioengineering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	C2008 December 31st	C2009 December 31st	R2010 December 31st	2011 December 31st	2012 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	265	296	306	213	145
Cost of Revenue
Gross Profit	174	167	158	99.8	44.4
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	201	237	276	253	194
Operating Profit	63.5	58.8	30.4	-39.9	-49.2
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	59.7	54.5	23.4	-67.9	-57.5
Provision for Income Taxes
Net Income After Taxes	47.1	41.3	14.1	-68.5	-59.7
Minority Interest
Net Income Before Extraordinary Items
Net Income	47.1	41.4	14.1	-67.4	-59.7
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	50.1	47.3	14.1	-67.4	-59.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	762	532	196	-251	-830
Dividends per Share